Remission of proteinuria improves prognosis in IgA nephropathy.
暂无分享,去创建一个
[1] G. Remuzzi,et al. Cellular responses to protein overload: key event in renal disease progression , 2004, Current opinion in nephrology and hypertension.
[2] G. Remuzzi,et al. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). , 1998, Kidney international.
[3] D. Cattran,et al. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[4] E. Bergstralh,et al. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[5] Eun Sun Lee,et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee's glomerular grading system. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[6] C. Schmid,et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. , 2001, Annals of internal medicine.
[7] G. D'Amico,et al. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. , 2004, Seminars in nephrology.
[8] G. Remuzzi,et al. Protein Overload-Induced NF-κB Activation in Proximal Tubular Cells Requires H2O2 through a PKC-Dependent Pathway , 2002 .
[9] P. Finne,et al. Factors associated with progression of IgA nephropathy are related to renal function--a model for estimating risk of progression in mild disease. , 2002, Clinical nephrology.
[10] David Roth,et al. A simplified equation to predict glomerular filtration rate from serum creatinine , 2000 .
[11] Masaki Kobayashi,et al. Natural history and risk factors for immunoglobulin a nephropathy in Japan , 1997 .
[12] J. Scholey,et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. , 2005, Journal of the American Society of Nephrology : JASN.
[13] N. Perico,et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. , 1999, American journal of physiology. Renal physiology.
[14] K. Chow,et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[15] K. Chow,et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] A. Koyama,et al. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[17] K Doqi,et al. clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification , 2002 .
[18] M. Wehrmann,et al. IgA nephritis: on the importance of morphological and clinical parameters in the long-term prognosis of 239 patients. , 1990, American journal of nephrology.
[19] H. Morita,et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. , 2003, Lancet.
[20] F. Lai,et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. , 2001, The American journal of medicine.
[21] R. Poveda,et al. Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[22] D. Tritchler,et al. Albumin activates ERK via EGF receptor in human renal epithelial cells. , 2005, Journal of the American Society of Nephrology : JASN.
[23] F. Locatelli,et al. Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .
[24] H. Shigematsu,et al. IgA nephropathy: prognostic significance of proteinuria and histological alterations. , 1983, Nephron.
[25] G. Remuzzi,et al. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? , 1990, Kidney international.
[26] F. Lai,et al. Prognostic indicators of IgA nephropathy in the Chinese--clinical and pathological perspectives. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[27] A. Jardine,et al. A tricontinental view of IgA nephropathy. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[28] É. Renoult,et al. IgA nephropathy: prognostic classification of end-stage renal failure. L'Association des Néphrologues de l'Est. , 1997 .
[29] G. D'Amico,et al. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[30] Regional program for the study of glomerulonephritis. Central Committee of the Toronto Glomerulonephritis Registry. , 1981, Canadian Medical Association journal.
[31] A. Pisani,et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[32] K. Chan,et al. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. , 2003, The Journal of clinical investigation.
[33] Cockcroft Dw,et al. Prediction of Creatinine Clearance from Serum Creatinine , 1976 .
[34] G. D'Amico,et al. The commonest glomerulonephritis in the world: IgA nephropathy. , 1987, The Quarterly journal of medicine.
[36] L. Ibels,et al. IgA Nephropathy: Analysis of the Natural History, Important Factors in the Progression of Renal Disease, and a Review of the Literature , 1994, Medicine.
[37] Giuseppe Remuzzi,et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria , 1999, The Lancet.
[38] Tsuyoshi Watanabe,et al. The Product of Duration and Amount of Proteinuria (Proteinuria Index) Is a Possible Marker for Glomerular and Tubulointerstitial Damage in IgA Nephropathy , 2002, Nephron.
[39] E. Morales,et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. , 2003, Journal of the American Society of Nephrology : JASN.
[40] D. Cattran,et al. Predicting progression in IgA nephropathy. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[41] E. Jones,et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[42] C. Ponticelli,et al. Prognostic indicators in idiopathic IgA mesangial nephropathy. , 1986, The Quarterly journal of medicine.
[43] H. Bucht,et al. Deterioration rate in hypertensive IgA nephropathy: comparison of a converting enzyme inhibitor and beta-blocking agents. , 1991, Nephron.
[44] G. Remuzzi,et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. , 1998, Kidney international.
[45] Christopher H Schmid,et al. Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis , 2003, Annals of Internal Medicine.
[46] G. Remuzzi,et al. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. , 1991, Kidney international.
[47] J. Scholey,et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission. , 2004, Kidney international.
[48] Kdoqi Disclaimer. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[49] M. Nagata,et al. Heterogeneity of prognosis in adult IgA nephropathy, especially with mild proteinuria or mild histological features. , 2001, Internal medicine.
[50] K. Wong,et al. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. , 2000, Kidney international.
[51] H. Morita,et al. RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial , 2003, The Lancet.
[52] G. Remuzzi,et al. Protein overload-induced NF-kappaB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependent pathway. , 2002, Journal of the American Society of Nephrology : JASN.
[53] E. Bergstralh,et al. Predicting renal outcome in IgA nephropathy. , 1997, Journal of the American Society of Nephrology : JASN.
[54] F. Locatelli,et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. , 1996, The New England journal of medicine.
[55] G. Maschio,et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[56] M. Haas,et al. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.